Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
WH

WKN: A3EJG1 | ISIN: GB00BN455J50 | Ticker: P8W0
Frankfurt
16.11.26 | 08:12
4,800 Euro
-2,44 % -0,120
1-Jahres-Chart
WORLDWIDE HEALTHCARE TRUST PLC Chart 1 Jahr
5-Tage-Chart
WORLDWIDE HEALTHCARE TRUST PLC 5-Tage-Chart
RealtimeGeldBriefZeit
4,6205,00016.11.
PR Newswire
391 Leser
Artikel bewerten:
(2)

Worldwide Healthcare Trust PLC - Portfolio Holding uniQure N.V. Announces Filing Plans with U.S. Food & Drug Administration

Worldwide Healthcare Trust PLC - Portfolio Holding uniQure N.V. Announces Filing Plans with U.S. Food & Drug Administration

PR Newswire

LONDON, United Kingdom, June 18

18 June 2026

WORLDWIDE HEALTHCARE TRUST PLC

("WWH" or the "Company")

Portfolio Holding uniQure N.V. Announces Filing Plans with U.S. Food & Drug Administration

The Company notes the announcement on Wednesday, 17 June 2026 that uniQure N.V ("uniQure"), during a recent Type B meeting with the U.S. Food and Drug Administration (FDA), the FDA communicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a Biologics License Application (BLA) for the accelerated approval of AMT-130 in Huntington's disease (HD). This marks an important shift for the FDA, creating a pathway for a near-term regulatory filing that was otherwise not available under previous leadership of the FDA.

AMT-130 is an investigational treatment and is the first one-time administered gene therapy to enter clinical testing for the treatment of HD. AMT-130 has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA - the first RMAT designation for HD - as well as Breakthrough Therapy designation and Fast Track designation.

The Company's holding in uniQure represented 1.10% of the Company's net asset value (NAV) at the time of the announcement. In response to this development, the share price appreciated 78.4% to U.S.$48.16 (compared to a cost base of U.S.$16.74 which reflects multiple purchases made in March 2026) and represented 1.93% of NAV as of the close on 17 June 2026.

To sign up for WWH updates by email, please click here .

Enquiries:

Quill PR (Emma Taylor)

Public Relations

07758311972

wwh@quillpr.com

Frostrow Capital LLP

Company Secretary

020 3 008 4913

LEI: 5493003YBCY4W1IMJU04

© 2026 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.